middle.news
How Acrux’s $0.55M R&D Advance Fuels Hormone Therapy Breakthrough
10:22am on Thursday 12th of March, 2026 AEDT
•
Healthcare
Read Story
How Acrux’s $0.55M R&D Advance Fuels Hormone Therapy Breakthrough
10:22am on Thursday 12th of March, 2026 AEDT
Key Points
Received $0.55 million advance on FY26 R&D Tax Incentive
Advance covers period from October 2025 to February 2026
Represents approximately 80% of estimated rebate for the period
Funds to support Hormone Replacement Therapy development and working capital
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Acrux (ASX:ACR)
OPEN ARTICLE